Beta-2 Microglobulin—An Immunogenetic Marker of Inflammatory and Malignant Origin DONALD T

Total Page:16

File Type:pdf, Size:1020Kb

Beta-2 Microglobulin—An Immunogenetic Marker of Inflammatory and Malignant Origin DONALD T ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 12, No. 6 Copyright © 1982, Institute for Clinical Science, Inc. Beta-2 Microglobulin—An Immunogenetic Marker of Inflammatory and Malignant Origin DONALD T. FORMAN, Ph .D. Departments of Pathology, Biochemistry, and Nutrition University of North Carolina School of Medicine, Chapel Hill, NC 27514 ABSTRACT Major contributions have been made in the last few years to the knowl­ edge of the structure, fate and cellular origin of beta-2 microglobulin (B2M); but the question of its function still remains unclear. The concept of B2M being simply a marker of renal physiology seems less satisfactory when reference is made to its relationship to the immunogenetic system. Although assay of B2 M cannot be considered as a specific diagnostic tool, it still may be regarded as a useful parameter in monitoring inflammatory, malignant, and auto-immune disease activity. Introduction Structure and Function Beta-2 microglobulin (B2M) was iso­ Beta-2 microglobulin is a protein of low lated in 1964 by Berggard7 from the relative molecular weight (Mr 11800) that urine of patients with Wilson’s disease or is present in small amounts of normal chronic cadmium poisoning. Its charac­ urine, serum, and other biological fluids. terization in 1968 determined that it con­ It is structurally related to immunoglobu­ sisted of a single polypeptide chain of lin G25 and to the cell-surface histocom­ about 100 amino acids.4 Research regard­ patibility antigens. It is synthetized by all ing this particular microprotein has nucleated cells and is present on their sur­ evolved along two lines. The first, mostly face. Its biological role remains unclear. clinical, established its importance as a At least 30 different microproteins origi­ marker of renal function.24 The more nating from plasma have been identified recent, more fundamental, led to the dis­ since 1964 in the urine of healthy individ­ covery of its close association with immu­ uals.13 With its 11800 molecular weight noglobulins and cell surface histocom­ and a 16 A size, B2M is one of the small patibility antigens.22 Although the two sized proteins ideally designed to pass areas overlap, various aspects of beta-2 freely through the glomerular sieve. Some microglobulin and its relationship to the physicochemical properties of B2M are immunogenetic system will be reviewed. listed in table I. 0091-7370/82/1100-0447 $00.90 © Institute for Clinical Science, Inc. 448 FORMAN TABLE I of almost all nucleated circulating cells, Physiochemical Properties of Beta-2 Microglobulin mesenchymal and epithelial cells as well.14 Although there is a significant amino acid Electrophoretic mobility at Like beta-globulin homology between B2 M and the constant pH 8.6 Isoelectric pH 5.4 - 5.7 domains of IgG, B2 M does not react with Molecular weight 11600 - 11800 Sedimentation coefficient (S20w ) 1-65 antisera to the heavy or light chains of the Carbohydrate content 0 immunoglobulins. In table II are de­ N 2 content 16.3 percent Molecular stokes radius scribed various immunologic properties 16Á of B2M. The small size of B2M has made it a suitable candidate for determining the se­ Clinical Chemistry of B2M quence of the amino acid residues that Beta-2 microglobulin circulates in the make up the peptide (figure 1). From stud­ blood at detectable levels and is also pres­ ies of the amino acid sequences of B2M, it ent in urine, saliva, colostrum, and am- appears that the arrangement of the 100 niotic fluid. In healthy subjects, the con­ amino acids of this moiety bears a very centration of B2M in serum fluctuates striking homology with the constant do­ within a narrow range of values, from 900 mains of the heavy and light chains of to 2800 ¡mg per L.13 The urine range is 6.0 the immunoglobulins, especially with the to 300 ¡ig per L. These values appear to be CH3 domain.28 However, the circulating independent of the immunoassay used. B2M does not stem from a splitting of Determination of B2 M in human urine or immunoglobulins. In fact it has been serum was initially by single radial im­ shown to be present on the surface of munodiffusion,6 but this method is not lymphocytes23 and later on the surface sensitive enough for detecting B2M in F ig u re 1. Structural char­ acteristics of Beta2-micro- globulin. (Taken from Poulik, M. D. and Bloom, A. D. J. Immunol. 110: 1430-1433, 1973.) Amino-acid residues: 100 BETA-2 MICROGLOBULIN— AN IMMUNOGENETIC MARKER 449 reference population urine without a pre­ TABLE II liminary concentration step. Radioim­ Immunologic Properties of Beta-2 Microblogulin (B2M) munoassay (RIA) methods were then de­ Amino acid homology and structural similarity to CH3 veloped which can accurately measure region of igG B2M in normal urine or serum without Antigenically distinct from IgG B 2 M does not bind with Staph A protein sample preconcentration. B 2 M is non-covalently linked to major histo­ The two available radioimmunoassay compatibility antigens (HLA) on the surface of (RIA) methods for B2M are the solid phase nucleated cells RIA technique of Evrin12 and the double­ antibody method of Shuster et al.32 Solid phase RIA has also been commercial­ detection of tubular damage from exces­ ized.* The disadvantages of the radioiso­ sive exposure to cadmium. Recent reports tope methods (short shelf-life, cost, health have also implicated increased B2M in hazards, time of assay [six to eight hours]) cerebrospinal fluid of patients with leuke­ have been previously discussed.15 A mia or lymphoma and early relapse in the lymphocytotoxicity inhibition technique central nervous system.19 Increased B2M for determining B2M has recently been has been reported in Crohn’s disease,11 proposed,10 but the method is less accu­ Sjogren’s syndrome,20 and rheumatoid rate and sensitive than RIA and gives arthritis.18 a semi-quantitative estimate. Bernard5 has recently published a highly sensitive method for the determination of B2 M in Beta-2 Microglobulin and Its human urine or serum based on the direct Relationship to the agglutination by B2M of latex particles on Immunogenetic System which an antibody against B2M is ab­ Welsh et al36 demonstrated that lym­ sorbed. The agglutination is quantitated phocytes in culture produce B2 M and this by counting the remaining unagglutin­ production could be stimulated by mito- ated particles or by turbidimetry. genic substances. Peterson25 showed that Interindividual variations in B2M, still B2M is part of the major histocompati­ unexplained, exist, but in a given refer­ bility cell-bound human leukocyte anti­ ence individual the level is stable. Serum gen (HLA) complex responsible to a great levels of B2 M are independent of body extent for immuno-rejection of trans­ mass or sex but are slightly increased in planted organs and tissues in non-geneti- elderly persons.34 The narrow reference cally related hosts. Although conflicting range of values are higher in malignant data, mainly owing to the methodology of disorders,34 particularly in multiple mye­ cell-bound HLA solubilization, have ap­ loma and monocytic leukemia. Elevated peared,26 the proposed structure of HLA values of serum B2M are considered a antigens has been postulated.10 Human very sensitive indicator of the impairment leukocyte antigen is composed of two of glomerular filtration rate.3,37 Healthy glycopeptide chains, so-called heavy subjects excrete very small quantities of chains, carrying the antigenic specificity B2M in urine (6 to 300 /«.g per L)13 but its and linked together through a S-S-bond excretion increases considerably in tubu­ embedded in the cell surface membrane. lar dysfunction, as observed in chronic Each of the heavy chains is linked, seem­ cadmium poisoning, Fanconi’s syndrome, ingly through a non-covalent bond, to a so- Balkan nephropathy, and Wilson’s dis­ called light chain which is precisely B2 M. ease.21,27 In occupational medicine, B2M The heavy chain has allotype variants in urine is the most sensitive test for early whereas the light chain has not; in other * Phadebas, B2 Micro Test, Pharmacia Diagnostic words, different HLAs bear the same A.B., Uppsala, Sweden. B2M. It appears that HLA is always bound 450 FORMAN to B2 M and the same situation exists in the in females than in males of each patient equivalent histocompatibility system of group. After statistical correction for these the mouse. A common ancestor gene cod­ age and sex effects, mean values for B2M ing for the 100 amino acid sequence of remained significantly higher in each of immunoglobulins and surface antigens the cancer groups than in their benign has been suggested.2 controls. Patients with more advanced breast cancer had higher levels of serum B2M than those subjects with early dis­ B2M in Solid Malignancies ease. This was true for patients with stom­ Several studies indicate that in patients ach cancer compared to those with colo­ with a wide variety of malignant tumors, rectal carcinoma. A possible interpretation serum B2M levels may be abnormally of these findings is that B2M concentra­ elevated as compared to those of age- tions increased with increasing tumor bulk matched controls.34 In primary bronchial and, therefore, this determination may be cancer, 44 percent of cancer patients had of value in the treatment and management elevated serum levels when compared to of cancer patients. their controls which had an elevated B2 M Studies relating differences in the cell in 11 percent of cases.31 Serum B2M levels surface of malignant cells with normal were measured by RIA in patients with cells suggest that solid and superficial various malignant neoplasms, ascites, and basal cell carcinomas lack immuno-reac- also with definite or suspected hepatoma tive B2M on the cell surface.
Recommended publications
  • Supplementary Information Changes in the Plasma Proteome At
    Supplementary Information Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease Julia Muenchhoff1, Anne Poljak1,2,3, Anbupalam Thalamuthu1, Veer B. Gupta4,5, Pratishtha Chatterjee4,5,6, Mark Raftery2, Colin L. Masters7, John C. Morris8,9,10, Randall J. Bateman8,9, Anne M. Fagan8,9, Ralph N. Martins4,5,6, Perminder S. Sachdev1,11,* Supplementary Figure S1. Ratios of proteins differentially abundant in asymptomatic carriers of PSEN1 and APP Dutch mutations. Mean ratios and standard deviations of plasma proteins from asymptomatic PSEN1 mutation carriers (PSEN1) and APP Dutch mutation carriers (APP) relative to reference masterpool as quantified by iTRAQ. Ratios that significantly differed are marked with asterisks (* p < 0.05; ** p < 0.01). C4A, complement C4-A; AZGP1, zinc-α-2-glycoprotein; HPX, hemopexin; PGLYPR2, N-acetylmuramoyl-L-alanine amidase isoform 2; α2AP, α-2-antiplasmin; APOL1, apolipoprotein L1; C1 inhibitor, plasma protease C1 inhibitor; ITIH2, inter-α-trypsin inhibitor heavy chain H2. 2 A) ADAD)CSF) ADAD)plasma) B) ADAD)CSF) ADAD)plasma) (Ringman)et)al)2015)) (current)study)) (Ringman)et)al)2015)) (current)study)) ATRN↓,%%AHSG↑% 32028% 49% %%%%%%%%HC2↑,%%ApoM↓% 24367% 31% 10083%% %%%%TBG↑,%%LUM↑% 24256% ApoC1↓↑% 16565% %%AMBP↑% 11738%%% SERPINA3↓↑% 24373% C6↓↑% ITIH2% 10574%% %%%%%%%CPN2↓%% ↓↑% %%%%%TTR↑% 11977% 10970% %SERPINF2↓↑% CFH↓% C5↑% CP↓↑% 16566% 11412%% 10127%% %%ITIH4↓↑% SerpinG1↓% 11967% %%ORM1↓↑% SerpinC1↓% 10612% %%%A1BG↑%%% %%%%FN1↓% 11461% %%%%ITIH1↑% C3↓↑% 11027% 19325% 10395%% %%%%%%HPR↓↑% HRG↓% %%% 13814%% 10338%% %%% %ApoA1 % %%%%%%%%%GSN↑% ↓↑ %%%%%%%%%%%%ApoD↓% 11385% C4BPA↓↑% 18976%% %%%%%%%%%%%%%%%%%ApoJ↓↑% 23266%%%% %%%%%%%%%%%%%%%%%%%%%%ApoA2↓↑% %%%%%%%%%%%%%%%%%%%%%%%%%%%%A2M↓↑% IGHM↑,%%GC↓↑,%%ApoB↓↑% 13769% % FGA↓↑,%%FGB↓↑,%%FGG↓↑% AFM↓↑,%%CFB↓↑,%% 19143%% ApoH↓↑,%%C4BPA↓↑% ApoA4↓↑%%% LOAD/MCI)plasma) LOAD/MCI)plasma) LOAD/MCI)plasma) LOAD/MCI)plasma) (Song)et)al)2014)) (Muenchhoff)et)al)2015)) (Song)et)al)2014)) (Muenchhoff)et)al)2015)) Supplementary Figure S2.
    [Show full text]
  • Tests for the Evaluation of Preterm Labor and Premature Rupture of Membranes
    Medical Coverage Policy Effective Date ............................................. 7/15/2021 Next Review Date ....................................... 7/15/2022 Coverage Policy Number .................................. 0099 Tests for the Evaluation of Preterm Labor and Premature Rupture of Membranes Table of Contents Related Coverage Resources Overview .............................................................. 1 Recurrent Pregnancy Loss: Diagnosis and Treatment Coverage Policy ................................................... 1 Ultrasound in Pregnancy (including 3D, 4D and 5D General Background ............................................ 2 Ultrasound) Medicare Coverage Determinations .................. 13 Coding/Billing Information .................................. 13 References ........................................................ 15 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ
    [Show full text]
  • Pathological Conditions Involving Extracellular Hemoglobin
    Pathological Conditions Involving Extracellular Hemoglobin: Molecular Mechanisms, Clinical Significance, and Novel Therapeutic Opportunities for alpha(1)-Microglobulin Gram, Magnus; Allhorn, Maria; Bülow, Leif; Hansson, Stefan; Ley, David; Olsson, Martin L; Schmidtchen, Artur; Åkerström, Bo Published in: Antioxidants & Redox Signaling DOI: 10.1089/ars.2011.4282 2012 Link to publication Citation for published version (APA): Gram, M., Allhorn, M., Bülow, L., Hansson, S., Ley, D., Olsson, M. L., Schmidtchen, A., & Åkerström, B. (2012). Pathological Conditions Involving Extracellular Hemoglobin: Molecular Mechanisms, Clinical Significance, and Novel Therapeutic Opportunities for alpha(1)-Microglobulin. Antioxidants & Redox Signaling, 17(5), 813-846. https://doi.org/10.1089/ars.2011.4282 Total number of authors: 8 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Tissue Distribution of Human Α1 -Microglobulin
    Tissue Distribution of Human α1-Microglobulin Kimiteru Takagi, … , Toshihiko Shimoda, Toshio Shikata J Clin Invest. 1979;63(2):318-325. https://doi.org/10.1172/JCI109305. Research Article Human α1-microglobulin was isolated from the urine of patients with tubular proteinuria, and its molecular weight was established by sodium dodecyl sulfate-polyacrylamide gel electrophoresis at 33,000 daltons. The carbohydrate content was 21.7%. Anti-α1-microglobulin serum was prepared and observed to react monospecifically in gel diffusion to purified α1-microglobulin, as well as to normal human serum and urine. Sera from the domestic chicken, mouse, rat, rabbit, dog, calf, cow, goat, sheep, and horse, however, did not react to anti-α1-microglobulin serum in immunodiffusion. The lymphocyte culture supernate was found to contain α1-microglobulin. Both thymus-derived(T)- and bone marrow- derived(B)-lymphocyte culture media clearly displayed a specific precipitin line against anti-α1-microglobulin serum when tested with the Ouchterlony immunodiffusion method. The tissue distribution of α1-microglobulin was studied under immunofluorescence, and a positive staining was recognized on the lymphocyte surface. Identical staining patterns were noted on both T and B lymphocytes, though B lymphocytes took a more intense stain. It would thus seem quite possible that lymphocytes are the primary source of α1-microglobulin and that this is filtered through the glomerular basement membrane and partly reabsorbed by the renal tubules. This, then, would suggest the possibility
    [Show full text]
  • The Double-Edged Sword of Beta2-Microglobulin in Antibacterial Properties and Amyloid Fibril-Mediated Cytotoxicity
    International Journal of Molecular Sciences Review The Double-Edged Sword of Beta2-Microglobulin in Antibacterial Properties and Amyloid Fibril-Mediated Cytotoxicity Shean-Jaw Chiou 1,2,*, Huey-Jiun Ko 1,2, Chi-Ching Hwang 1,2 and Yi-Ren Hong 1,2,3,4,* 1 Department of Biochemistry, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan; [email protected] (H.-J.K.); [email protected] (C.-C.H.) 2 Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan 3 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan 4 Department of Biological Sciences, National Sun Yat-Sen University, Kaohsiung 804, Taiwan * Correspondence: [email protected] (S.-J.C.); [email protected] (Y.-R.H.) Abstract: Beta2-microglobulin (B2M) a key component of major histocompatibility complex class I molecules, which aid cytotoxic T-lymphocyte (CTL) immune response. However, the majority of studies of B2M have focused only on amyloid fibrils in pathogenesis to the neglect of its role of antimicrobial activity. Indeed, B2M also plays an important role in innate defense and does not only function as an adjuvant for CTL response. A previous study discovered that human aggregated B2M binds the surface protein structure in Streptococci, and a similar study revealed that sB2M-9, derived from native B2M, functions as an antibacterial chemokine that binds Staphylococcus aureus. An investigation of sB2M-9 exhibiting an early lymphocyte recruitment in the human respiratory epithelium with bacterial challenge may uncover previously unrecognized aspects of B2M in the Citation: Chiou, S.-J.; Ko, H.-J.; body’s innate defense against Mycobactrium tuberculosis.
    [Show full text]
  • Breakdown of Supersaturation Barrier Links Protein Folding to Amyloid Formation
    ARTICLE https://doi.org/10.1038/s42003-020-01641-6 OPEN Breakdown of supersaturation barrier links protein folding to amyloid formation Masahiro Noji1,11, Tatsushi Samejima1, Keiichi Yamaguchi1,12, Masatomo So 1, Keisuke Yuzu2, Eri Chatani2, Yoko Akazawa-Ogawa3, Yoshihisa Hagihara3, Yasushi Kawata4, Kensuke Ikenaka5, Hideki Mochizuki5, ✉ József Kardos6, Daniel E. Otzen 7, Vittorio Bellotti 8,9, Johannes Buchner 10 & Yuji Goto 1,12 1234567890():,; The thermodynamic hypothesis of protein folding, known as the “Anfinsen’s dogma” states that the native structure of a protein represents a free energy minimum determined by the amino acid sequence. However, inconsistent with the Anfinsen’s dogma, globular proteins can misfold to form amyloid fibrils, which are ordered aggregates associated with diseases such as Alzheimer’s and Parkinson’s diseases. Here, we present a general concept for the link between folding and misfolding. We tested the accessibility of the amyloid state for various proteins upon heating and agitation. Many of them showed Anfinsen-like reversible unfolding upon heating, but formed amyloid fibrils upon agitation at high temperatures. We show that folding and amyloid formation are separated by the supersaturation barrier of a protein. Its breakdown is required to shift the protein to the amyloid pathway. Thus, the breakdown of supersaturation links the Anfinsen’s intramolecular folding universe and the intermolecular misfolding universe. 1 Institute for Protein Research, Osaka University, Yamadaoka 3-2, Suita, Osaka 565-0871, Japan. 2 Department of Chemistry, Graduate School of Science, Kobe University, Hyogo 657-8501, Japan. 3 National Institute of Advanced Industrial Science and Technology (AIST), 1-8-31 Midorigaoka, Ikeda, Osaka 563- 8577, Japan.
    [Show full text]
  • Regina Qu'appelle Health Region Tests
    Regina Qu'Appelle Health Region Tests Acetaminophen Haptoglobin Alpha-Feto Protein (AFP) HbA1C AGBM Hemoglobin Electrophoresis Albumin Hemosiderin (urine) Alkaline Phosphatase (ALP) Kleihauer-Betke Test Alpha-1 Antitrypsin Lactate Alanine Aminotransferase (ALT) Luteinizing Hormone (LH) Amylase Lipid Panel (Chol, Trig, HDL, LDL ) Anti-mitochondrial antibodies Lithium Anti-RNP Liver Panel (Bili, ALT, ALP) Anti-scleroderma-70 antibodies Magnesium Anti-smooth muscle antibodies Malaria Blood Smear APTT - fresh specimen Methemalbumin Aspartate aminotransferase (AST) Microalbumin Bence Jones Protein (50-100mls 24 hour urine) Microalbumin/Creatinine Ratio Beta HCG Hypercoagulation Studies Direct Bilirubin Osmolality (Serum and Urine) Total Bilirubin Peripheral Smear review by pathologist CA-125 Phenobarbital Calcium Phenytoin (Dilantin) Carbamazepine (Tegretol) Phosphorus CBC Prolactin Carcinoembryonic Antigen (CEA) Prostate Specific Antigen (PSA) Cholinesterase w/ Dibucaine # Prothrombin Time Creatine kinase (CK) Protein Electrophoresis (PE, SPE) Creatinine (Serum and Urine) Protein Creatinine Clearance Renal Panel Cryoglobulin Reticulocyte Count Cyclosporin Sickle Cell Screen D-Dimer Sirolimus Digoxin (Lanoxin) Tacrolimus Electrolytes Theophylline Estradiol Thyroid Screen (TSH) Ferritin Tobramycin FSH Urea G-6-PD Uric Acid Gentamycin Valproic Acid (Epival, Depakene) G-Glutamyl Transferase (GGT) Vancomycin Glucose Viscosity Frozen Specimens Amikacin Factor Assays Lupus Anticoagulant Ammonia Fibrinogen Protein C Anticardiolipin Ab Heparin Assay Protein S Antiphospholipid Ab Hypercoagulation Screen Von Willebrand's Factor Anti-thrombin III H. Pylori Beta-2 Microglobulin Lactic Acid For more information refer to the RQHR Laboratory Services Manual or access the link below: RQHR Laboratory Specimen Requirements LABLisOP2002A3 RQHR Tests Laboratory Services, Regina Qu'Appelle Health Region 03/05/2016.
    [Show full text]
  • Quantitative Plasma Proteomics of Survivor and Non-Survivor COVID-19 Patients Admitted to Hospital Unravels Potential Prognostic
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.26.20248855; this version posted January 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Quantitative plasma proteomics of survivor and non-survivor COVID- 19 patients admitted to hospital unravels potential prognostic biomarkers and therapeutic targets Daniele C. Flora &1,4, Aline D. Valle &1, Heloisa A. B. S. Pereira &1, Thais F. Garbieri 1, Nathalia R. Buzalaf 1, Fernanda N. Reis1, Larissa T. Grizzo 1, Thiago J. Dionisio 1, Aline L. Leite 2, Virginia B. R. Pereira 3, Deborah M. C. Rosa 4, Carlos F. Santos 1, Marília A. Rabelo Buzalaf *1 1 Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, SP, Brazil. 2 Nebraska Center for Integrated Biomolecular Communication, University of Nebraska-Lincoln, Lincoln, NE, USA. 3 Adolfo Lutz Institute, Center of Regional Laboratories II - Bauru, SP, Brazil 4 Bauru State Hospital, Bauru, SP, Brazil * Corresponding author: [email protected]. Tel: +55 14 32358346 & Joint first authors Abstract The development of new approaches that allow early assessment of which cases of COVID-19 will likely become critical and the discovery of new therapeutic targets are urgent demands. In this cohort study, we performed proteomic and laboratorial profiling of plasma from 163 patients admitted to Bauru State Hospital (Bauru, SP, Brazil) between May 4th and July 4th, 2020, who were diagnosed with COVID-19 by RT-PCR nasopharyngeal swab samples.
    [Show full text]
  • Changes in the Plasma Proteome at Asymptomatic And
    www.nature.com/scientificreports OPEN Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Received: 22 September 2015 Accepted: 10 June 2016 Alzheimer’s disease Published: 06 July 2016 Julia Muenchhoff 1, Anne Poljak1,2,3, Anbupalam Thalamuthu1, Veer B. Gupta4,5, Pratishtha Chatterjee4,5,6, Mark Raftery2, Colin L. Masters7, John C. Morris8,9,10, Randall J. Bateman8,9, Anne M. Fagan8,9, Ralph N. Martins4,5,6 & Perminder S. Sachdev1,11 The autosomal dominant form of Alzheimer’s disease (ADAD) is far less prevalent than late onset Alzheimer’s disease (LOAD), but enables well-informed prospective studies, since symptom onset is near certain and age of onset is predictable. Our aim was to discover plasma proteins associated with early AD pathology by investigating plasma protein changes at the asymptomatic and symptomatic stages of ADAD. Eighty-one proteins were compared across asymptomatic mutation carriers (aMC, n = 15), symptomatic mutation carriers (sMC, n = 8) and related noncarriers (NC, n = 12). Proteins were also tested for associations with cognitive measures, brain amyloid deposition and glucose metabolism. Fewer changes were observed at the asymptomatic than symptomatic stage with seven and 16 proteins altered significantly in aMC and sMC, respectively. This included complement components C3, C5, C6, apolipoproteins A-I, A-IV, C-I and M, histidine-rich glycoprotein, heparin cofactor II and attractin, which are involved in inflammation, lipid metabolism and vascular health. Proteins involved in lipid metabolism differed only at the symptomatic stage, whereas changes in inflammation and vascular health were evident at asymptomatic and symptomatic stages.
    [Show full text]
  • Structural Studies of Heterogeneous Amyloid Species of Lysozymes and De Novo Protein Albebetin and Their Cytotoxicity
    Structural studies of heterogeneous amyloid species of lysozymes and de novo protein albebetin and their cytotoxicity Vladimir Zamotin Department of Medical Biochemistry and Biophysics Umeå University Umeå, Sweden 2007 Моей маме, жене и доче To my family 3 4 Abstract A number of diseases are linked to protein folding problems which lead to the deposition of insoluble protein plaques in the brain or other organs. These diseases include prion diseases such as Creutzfeld-Jakob disease, Alzheimer's disease, Parkinson's disease and type II (non-insulin dependent) diabetes. The protein plaques are found to consist of amyloid fibrils - cross-beta-sheet polymers with the beta- strands arranged perpendicular to the long axis of the fibre. Studies of ex vivo fibrils and fibrils produced in vitro showed that amyloid structures possess similar tinctorial and morphological properties. These suggest that the ability to form amyloid fibrils is an inherent property of polypeptide chains. The aims of this thesis were to investigate the structural properties of cytotoxic amyloid and examine the involved mechanisms. The model proteins used in the studies were the equine and hen lysozymes and de novo designed protein albebetin. Lysozymes are naturally ubiquitous proteins. Equine lysozyme belongs to an extended family of structurally related lysozymes and α-lactalbumins and can be considered as an evolutional bridge between them. Hen lysozyme is one of the most characterized protein and its amyloidogenic properties were described earlier. De novo protein albebetin and its constructs are designed to perform the function of grafted polypeptide sequence. Fibrils of equine lysozyme are formed at acidic pH and elevated temperatures where a partially folded molten globule state is populated.
    [Show full text]
  • Confidential to This Report 2 to Whom Correspondence Should Be Addressed: Robert D
    AACC Guidance Document on Laboratory Testing for the Assessment of Preterm Delivery Authors: Christopher Farnsworth1, PhD, DABCC, FAACC Department of Pathology and Immunology Washington University in St. Louis St. Louis, MO Erin E. Schuler1, PhD Department of Pathology and Laboratory Medicine University of Kentucky Medical Center Lexington, KY Alison Woodworth, PhD, DABCC, FAACC Department of Pathology and Laboratory Medicine University of Kentucky Medical Center Lexington, KY Joely Straseski, PhD, MT(ASCP), DABCC, FAACC Department of Pathology University of Utah School of Medicine Salt Lake City, UT E. Rebecca Pschirrer, MD, MPH Department of Obstetrics and Gynecology Dartmouth-Hitchcock Health System Lebanon, NH Robert D. Nerenz2, PhD, DABCC Department of Pathology and Laboratory Medicine Dartmouth-Hitchcock Health System Lebanon, NH 1 These authors contributed equallyConfidential to this report 2 To whom correspondence should be addressed: Robert D. Nerenz, Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Health System, Lebanon, NH 03756 Fax: 603-650-7214; Email: [email protected] Abstract Identifying women with preterm labor that will go on to deliver prematurely is crucial to improve outcomes for mother and baby and save healthcare resources. Even among those with symptoms, the number of women who deliver preterm is low, and thus the low positive predictive value (PPV) and high negative predictive value (NPV) associated with available biomarkers does not substantially reduce the uncertainty of the clinical diagnosis. While there is some promise in the use of fetal fibronectin (fFN), interleukin 6 (IL-6) or placental alpha macroglobulin 1 (PAMG-1) for predicting preterm birth (PTB), their use is unlikely to provide considerable clinical value in populations with a low prevalence.
    [Show full text]
  • TWO NOVEL MECHANISMS of MHC CLASS I DOWN- REGULATION in HUMAN CANCER: ACCELERATED DEGRADATION of TAP-1 Mrna and DISRUPTION of TAP-1 PROTEIN FUNCTION
    TWO NOVEL MECHANISMS OF MHC CLASS I DOWN- REGULATION IN HUMAN CANCER: ACCELERATED DEGRADATION OF TAP-1 mRNA AND DISRUPTION OF TAP-1 PROTEIN FUNCTION DISSERTATION Presented in Partial Fulfillment of the Requirement for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University by Tianyu Yang * * * * * The Ohio State University 2004 Dissertation Committee: Approved by Professor Pan Zheng, Adviser Professor Yang Liu Professor Joan Durbin Professor Xuefeng Bai Adviser Department of Pathology Professor William Lafuse ABSTRACT Both viruses and tumors evade cytotoxic T lymphocyte (CTL)-mediated host immunity by down-regulation of major histocompatibility complex (MHC) class I antigen presentation machinery. The transporter associated with antigen processing (TAP), a heterodimer of TAP-1 and TAP-2, plays essential role in the MHC class I- restricted antigen presentation pathway by translocating antigenic peptides from cytosol into the ER lumen, where the assembly of MHC class I complex takes place. TAP deficiency is a frequent observation in human cancers, which is one of the causes of MHC class I down-regulation. However, the underlying molecular mechanism has been limited. In search for novel mechanisms of TAP deficiency and MHC class I down- regulation in human cancer cells, we characterized an MHC class I-deficient melanoma cell line SK-MEL-19. The expression of TAP-1 mRNA was found deficient in this cell line even after interferon-gamma (IFN-γ) stimulation, despite its active transcription. This abnormality is caused by a single nucleotide deletion at position +1489 of the TAP- 1 gene, which results in rapid degradation of the TAP-1 mRNA.
    [Show full text]